Associated Genetic Biomarkers
IDH2 R172N is a predictive biomarker for use of enasidenib in patients.
Of the therapies with IDH2 R172N as a predictive biomarker, 1 is FDA-approved and 1 has NCCN guidelines in at least one clinical setting.
Acute myeloid leukemia has the most therapies targeted against IDH2 R172N or its related pathways .
Acute Myeloid Leukemia -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Refractory (FDA, NCCN), Relapse (FDA, NCCN)|
|Note: Enasidenib is an IDH2 inhibitor approved by the FDA for treatment of adult patients with relapsed or refractory AML with an IDH2 mutation.|
Significance of IDH2 R172N in Diseases
Acute Myeloid Leukemia +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.